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Abstract Prevalence and phenotype of BRCA mutation
can vary by race. The purpose of this study is to evaluate
the prevalence of BRCA1/2 mutations in non-familial
breast cancer patients with high risks in Korea. A subset of
758 patients was selected for this study from the KOHBRA
nationwide multicenter prospective cohort study. Muta-
tions in BRCA1/2 genes were tested using fluorescent-
conformation sensitive gel electrophoresis, denaturing high
performance liquid chromatography or direct sequencing.
Mutation of BRCA1/2 genes were identified in 65 (8.6%)
patients among total 758 patients [BRCA1 mutation: 25
(3.3%), BRCA2 mutation: 40 (5.3%)]. According to risk
groups, mutation of BRCA1/2 genes were identified in 53
(8.5%) of 625 early onset patients (age B40), in 22 (17.7%)
of 124 bilateral breast cancer patients, in 3 (50.0%) of 6
breast and ovarian cancer patients, in one (5.9%) of 17
male breast cancer patients, in 5 cases (7.6%) of 66 mul-
tiple organ cancer patients. The most common mutation
was 509C[A for BRCA1 and 7708C[T for BRCA2. The
prevalence of BRCA1/2 mutations by age in early onset
patients was significantly different (age \35 vs age C35;
10.0 vs 2.9%, p = 0.0007). BRCA1/2 mutations for non-
familial Korean breast cancer patients were detected at a
high rate, particularly, in patients with early onset of less
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than 35 years of age, bilateral breast cancer, and breast and
ovarian cancer. Individualized genetic counseling should
be offered for non-familial breast cancer patients with these
risk factors.
Keywords BRCA1  BRCA2  Hereditary breast cancer 
Korean  Non-familial  Prevalence
Introduction
Although hereditary breast cancer is responsible for about
5–10% of all breast cancers, women carrying BRCA1 and
BRCA2 gene mutations have especially high risk of breast
cancer development. Mutations in BRCA1/2 genes have an
estimated lifetime risk of breast cancer between 60 and 85%,
and a lifetime risk of ovarian cancer between 26 and 54% for
BRCA1 and between 10 and 23% for BRCA2. They are
responsible for about 45% of families with multiple cases of
breast cancer and up to 90% of families with both breast and
ovarian cancer [1–4]. There are specific clinical and patho-
logical features associated with hereditary BRCA1 or BRCA2
mutation associated breast cancers [5–7].
Genetic counseling and genetic testing to identify
BRCA1 and BRCA2 gene mutations in high risk (a signif-
icant risk C10% of mutation) patients is widely available
and commonly employed in the US and Europe [1, 8].
Management for breast cancer patients with a BRCA
mutation should be established based on the clinicopatho-
logic status as well as the result of genetic testing. Both
prophylactic mastectomy and prophylactic oophorectomy
are performed in approximately one-third and one half of
mutation carriers in Western countries, respectively [9, 10].
However, decision-making for specific management should
be done by a physician knowledgeable about the implica-
tions and lifetime risks of both breast and ovarian cancer.
There are some limitations to applying the clinical
practice guidelines for genetic testing based on data from
Western countries due to a lack of BRCA mutation data in
breast cancer patients of Korean and other racial back-
grounds [1, 11, 12]. First, the clinicopathological features
associated with breast cancer may differ between races. For
example, the proportion of triple negative breast cancer is
higher in African-Americans and Asians compared to
Caucasian Americans [13, 14]. Although the incidence of
breast cancer in Asian countries, such as Korea, is lower
than in Europe and the US, the incidence of Korean breast
cancer has increased continuously by about threefold dur-
ing the last two decades. The most striking difference
compared to that of Western countries is that breast cancer
among Korean women develops at a younger age [15, 16].
Sixty percent of patients in Korea are premenopausal
compared to 30% in the United States. As ER-negative
breast cancers are more common in premenopausal
women, one may expect differences in frequencies of
molecular subtypes of breast cancer between Korean and
Caucasian women [13, 17]. There may be differences
between countries in terms of genetic–environment inter-
action for development of breast cancer, ethnic diet, or
environmental exposures. Consideration of family structure
between in Korea and in Western countries is also needed
because smaller family size makes family history less
useful for identification of germline genetic risk [18].
Prevalence and phenotype of BRCA mutation varies
according to country and race [19–21]. Several reports on
BRCA gene mutation in Korean breast cancer patients have
been published over a decade since a first report of BRCA1
among Korean pedigrees in 1995 [22–30]. The prevalence
of BRCA1 and BRCA2 mutations were reported in
2.5–3.1% for sporadic breast cancers, in 19.4–42.9% for
familial breast cancer patients with two or more affected
first- and second-degree relatives with breast or ovarian
cancers, and in 9.6–18.3% for early onset breast cancers.
BRCA1 and BRCA2 mutations were also identified in
15.4% for bilateral breast cancer and in 17.9% for multiple
organ cancer, and BRCA2 mutations were identified in 25%
for male breast cancer in one study [27]. However, the data
in high-risk breast cancer patients without family history of
breast or ovarian cancer did not accurately reflect the
prevalence of BRCA mutation in Korean breast cancer
patients because of the very small sample size. A large
scale multicenter study was needed to evaluate the preva-
lence of BRCA mutation among Korean breast cancer
patients nationwide.
The KOHBRA study was designed by the Korean Breast
Cancer Society to investigate the prevalence of BRCA1/2
mutations in several groups of subjects seen in high-risk
breast cancer clinics in Korea between 2007 and 2010 [31].
These groups included patients with a family history of
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breast or ovarian cancers, patients with non-familial breast
and ovarian cancer but with other risk factors of genetic
disease, and family members of breast cancer patients with
BRCA1/2 mutations. The KOHBRA study also investigated
the prevalence of ovarian cancer in females with BRCA1/2
mutations
The present study evaluated the prevalence of BRCA1
and BRCA2 mutations in the second KOHBRA group,
breast cancer patients without family history of breast




The nationwide prospective cohort ‘‘KOHBRA’’ study
accrued 1,967 subjects between May 2007 and May 2010
from 35 hospitals registered in the Korean Breast Cancer
Society. The overall protocol is described more in detail
in the interim report of the KOHBRA study [31, 32].
Inclusion criteria for this substudy are: patients without
family history of breast or ovarian cancer but with at least
one of the following risk factors for hereditary predispo-
sition; early onset breast cancer defined as diagnosis at or
younger than age 40, bilateral breast cancer, personal
history of breast and ovarian cancer, male breast cancer,
or cancer of multiple organs that include breast. This
study received IRB approval from the individual institutes
at the beginning of the study and consent from the study
patients at the time of enrollment. Patients who were
unable to communication or who did not return the
questionnaire were excluded. Seven hundred and fifty-
eight patients from the KOHBRA cohort met the criteria
for this study.
Among the 758 patients, 741 (97.8%) patients were
female and 17 (2.2%) patients were male. The breakdown
of the high-risk groups is shown in Table 1. There were
550 (72.6%) patients with early onset breast cancer, 67
(8.8%) patients with bilateral breast cancer, 42 (5.5%)
patients with cancer of multiple organs, 15 (2.0%) male
breast cancer patients, 5 (0.7%) patients with both breast
and ovarian cancer, and 79 (10.4%) patients having two or
more of these high genetic risk factors.
Collecting clinical data
The family history and epidemiological data was obtained by
a baseline questionnaire, the anthropometric data was mea-
sured, and the clinical information was collected by physi-
cian chart-reviews. Questionnaire included information
about basic clinical data, past history, familial cancer history,
life style, reproductive factors, social-psychological factors,
and history of complementary therapies, etc. Physical
information like body weight, height, body circumference,
and body composition was acquired via physical examina-
tion at the same time of questionnaire. Pedigree of at least
three generations was acquired via genetic counseling in all
patients. All the data was computerized and regularly
reviewed through quality control for missing or error data.
Follow-up data of a new cancer, recurrence, and mortality
was collected at 1 and 3 years after enrollment.
BRCA1 and BRCA2 genomic mutation analysis
Genomic DNA was extracted from the patients’ peripheral
blood. Mutations in BRCA1 and BRCA2 were scanned
through the 22 coding exons of BRCA1 and 26 coding
exons of BRCA2 using fluorescence-conformation sensitive
gel electrophoresis (F-CSGE) or denaturing high perfor-
mance liquid chromatography (DHPLC). Following iden-
tification of a subset of PCR products with aberrant
patterns, direct sequencing was performed in these DNA
fragments on an ABI3100 or ABI3700 (Applied Biosys-
tems, CA) or a MegaBACE500 (GE Healthcare, UK)
genetic analyzer, following the manufacturer’s instructions.
Scanning and direct sequencing of BRCA genes was per-
formed based on the institutes’ own protocol and equip-
ment. Some institutes performed direct sequencing through
the entire BRCA1 and BRCA2 genes. Among all 758
patients, an F-CSGE performed in 670 cases (88.4%),
DHPLC in 14 cases (1.8%), and direct sequencing in 74
cases (9.8%). In this study, the definition of a genetic
mutation is confined to the protein-truncating mutation and
the missense mutation, which have a confirmed association
to disease. Unclassified variants were not considered as a
genetic mutation.
Table 1 Classification of high-risk groups
High-risk classification No of
patients (%)
Early onset breast cancer (age B40 years) (E) 550 (72.6)
Bilateral breast cancer (B) 67 (8.8)
Male breast cancer (M) 15 (2)
Breast and ovarian cancer (BO) 5 (0.7)
Multiple organ cancer patients including breast (Mu) 42 (5.5)
Two or more of these high risksa 79 (10.4)
Total 758 (100.0)
a E ? B:53, E ? M:1, E ? BO:1, E ? Mu:19, B ? Mu:3, M ?
Mu:1, E ? B ? Mu:1
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Results
Prevalence of BRCA1 and BRCA2 mutations in high-
risk breast cancer patients without family history
of breast or ovarian cancer
Overall, mutation of BRCA1 or BRCA2 genes was identified
in 65 (8.6%) patients among 758 high-risk breast cancer
patients without family history of breast or ovarian cancer.
BRCA1 mutation was found in 25 (3.3%) patients and BRCA2
mutation was found in 40 (5.3%) patients. One patient had
both BRCA1 and BRCA2 mutations (Fig. 1).<Dummy
RefID="F_10549_2012_2001_Fig1_HTML
According to each high-risk group, mutation of BRCA1
and BRCA2 genes were identified in 53 (8.5%) of 625 early
onset patients, in 22 (17.7%) of 124 patients with bilateral
breast cancer, in 3 (50.0%) of 6 patients with breast and
ovarian cancer, in 1 (5.9%) of 17 male breast cancer
patients, in 5 (7.6%) of 66 patients with cancer of multiple
organs including breast, and in 19 (27.1%) of 79 patients
having two or more of these high risks (Table 2). Using
non-overlapping risk groups, mutation of BRCA1 or
BRCA2 genes were identified in 35 (6.4%) of 550 early
onset patients, in 5 (7.5%) of 67 patients with bilateral
breast cancer, in 2 (40.0%) of 5 patients with breast and
ovarian cancer, in 1 (6.7%) of 15 male breast cancer
patients, and in 3 (7.0%) of 42 patients with multiple organ
cancers including breast.
BRCA1 and BRCA2 mutation by risk groups
BRCA1 mutations were detected in 22 (3.5%) of 625 early
onset patients, in 7 (5.6%) of 124 patients with bilateral
breast cancer, in 1 (16.7%) of 6 patients with breast and
ovarian cancers, in 2 (3.0%) of 66 patients with multiple
organ cancers, and in 7 (8.9%) of 79 patients having two or
BRCA1 BRCA2
Fig. 1 Prevalence of BRCA1 and BRCA2 mutations in high-risk
breast cancer patients without family history of breast or ovarian
cancer. Overall BRCA1/2 mutations: 65/758 (8.6%), One patient
had both BRCA1 and BRCA2 mutations. UV unclassified variant
Table 2 BRCA1 and BRCA2
mutations according to high-risk
groups
a UV unverified mutation
b One patient had both BRCA1
and BRCA2 mutations
c Data of BRCA1 test in one
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more of these high-risk factors. There was no BRCA1
mutation detected among 17 male breast cancer patients.
BRCA2 mutations were detected in 31 (5.0%) early onset
patients, 15 (12.1%) patients with bilateral breast cancer, 2
(33.3%) patient with breast and ovarian cancer, 3 (4.6%)
patients with multiple organ cancers, 1 (5.9%) male breast
cancer patient, and 12 (15.2%) patients having two or more
of these high risks (Table 2).
BRCA1 and BRCA2 mutations in early onset breast
cancer patients
Patients with early onset breast cancer had a variety of
BRCA1 and BRCA2 mutations based on the combined risk
groups. Of 625 early onset patients, BRCA1 and BRCA2
mutations were detected in 35 (6.4%) of 550 patients
without other risks, in 16 (30.2%) of 53 patients with
bilateral breast cancer, in one (100%) patient who also had
ovarian cancer, and in one (5.3%) of 19 patients with
multiple organ cancers (Table 3).
According to age at diagnosis, BRCA1 and BRCA2
mutations were detected in 24.0% of patients 40 years or
younger with other risk factors and in 6.4% among early
onset patients without other risk factors. However, among
the early onset patients without other risk factors, BRCA1
and BRCA2 mutations were detected in 10.0% in patients
less than 35 years and in 2.9% in patients 35 years or older
(p = 0.0007) (Table 3).
In terms of age group, incidence of BRCA1/2 mutations
in patients 35 years or older showed a significant differ-
ence depending on whether other risks were combined or
not (22.9 vs 2.9%, p = \0.0001). On the other hand,
BRCA1/2 mutations in patients less than 35 years showed
high incidence rates regardless of the combined risks (25.9
vs 10%, p = 0.01) (Table 4).
We evaluated each patient’s family history to develop a
family structure variable to find whether a limited family
Table 3 BRCA1 and BRCA2 mutations in patients with early onset breast cancer diagnosed at B40 years













Early onset breast cancer
B40 yrs only (E)*
271 27 (10) 279 8 (2.9) 550 35 (6.4)
E ? Bilateral breast cancer 20 7 (35) 33 9 (27.3) 53 16 (30.2)
E ? Breast and ovarian cancer 0 0 1 1 (100) 1 1 (100)
E ? Multiple organ cancer 5 0 14 1 (7.1) 19 1 (5.3)
E ? Male breast cancer 1 0 0 0 1 0
E ? Bilateral breast cancer
? multiple organ cancer
1 0 0 0 1 0
Total 298 34 (11.4) 327 19 (5.8) 625 53 (8.5)
* p = 0.0007
Table 4 BRCA1/2 and BRCA2
mutations by age in patients
with early onset breast cancer
diagnosed at B40 years
a Other risks included early
onset, bilateral breast cancer,
male breast cancer, breast and
ovarian cancer, and multiple
organ cancer




C35 yrs With other risksa 11 37 48 \0.0001
No. (%) 22.9 77.1 14.7
Without other risks 8 271 279
No. (%) 2.9 97.1 85.3
Total 19 308 327
No. (%) 5.8 94.2 100
\35 yrs With other risks 7 20 27 0.01
No. (%) 25.9 74.1 9.1
Without other risks 27 243 270
No. (%) 10 90 90.9
Total 34 263 298
No. (%) 11.4 88.6 100
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structure affects BRCA1/2 mutation prevalence or not.
Limited family structure was defined as fewer than two
first- or second-degree female relatives surviving past age
45 years in either the maternal or paternal lineage. Other-
wise the patient was deemed to have an adequate family
structure [18]. BRCA1 and BRCA2 mutations did not show
different incidence between limited structure and adequate
structure according to family structure in early onset
patients (Table 5).
Possible candidates for founder mutation of BRCA1
and BRCA2 genes
Overall 43 mutations (18 BRCA1 genes and 25 BRCA2
genes) were identified in high-risk breast cancer patients
without a family history of breast or ovarian cancer. The
most common BRCA1 mutation gene was 509C[A, which
was identified separately in four unrelated patients.
1041delAGCinsT, 1630insG, 3746insA, and 5615del11insA
were identified separately in two unrelated patients. These
five BRCA1 genes accounted for 48% of the BRCA1 muta-
tions identified. The most common BRCA2 mutation gene
was 7708C[T, which was identified separately in six unre-
lated patients. 584delTTAA and 6952delGA was identified
in three unrelated patients. 2041dupA, 8542G[T, 1672A[T,
9219T[G, 9481delA, and 999del5 were separately identified
in two unrelated patients. These nine BRCA2 genes
accounted for 60% of the BRCA2 mutations identified
(Table 6).
Discussion
Overall mutation of BRCA1 and BRCA2 genes in high-risk
breast cancer patients without family history of breast or
ovarian cancer in this study was 8.6% (BRCA1: 3.3%,
BRCA2: 5.3%). The prevalence of genetic BRCA1/2 muta-
tion among non-familial patients with high-risk factors in
this study was more than three times higher than the 2.6%
prevalence observed for BRCA1/2 mutations in sporadic
breast cancer patients in Korea [25, 27, 28]. Genetic coun-
seling and testing for BRCA1 and BRCA2 gene mutation has
become an integral part of high-risk patient evaluation and
management for hereditary breast ovarian cancer [11, 33].
Guideline organizations, including NCCN and ASCO, have
advised targeting BRCA1 and BRCA2 testing to probands
whose probability of mutation carriage is approximately
10% or greater. However, there might be variation in
BRCA1/2 mutation prevalence across race and ethnicity for
breast cancer patients with high-risk factors, although the
prevalence of BRCA1/2 mutations is comparable among
sporadic breast cancer patients of African, Asian, White, and
Hispanic descent: approximately 1–4% per gene, with the
exception of Ashkenazi Jewish and Icelandic patients [33,
34]. There is a question of whether ethnic differences in
genetic, reproductive, or environmental exposures might
alter mutation penetrance, which could have significant
implications for clinical practice. Therefore, large data col-
lection of BRCA1/2 mutation prevalence and penetrance in
individual ethnic groups is necessary for applying individ-
ualized guideline for genetic counseling and testing, and
management in clinical practice.
This KOHBRA study showed the prevalence of BRCA1/
2 mutations in high-risk breast cancer patients without
family history of breast or ovarian cancer via a large
multicenter nationwide cohort study. Previous reports of
BRCA1/2 mutations in Korean breast cancer patients were
limited by small sample sizes, and the studies were per-
formed individually at various sites with different screen-
ing methods. Overall mutation of BRCA1/2 genes in high-
risk breast cancer patients without family history of breast
or ovarian cancer in this study was 8.6%. On the other
hand, the prevalence of BRCA1/2 mutations among breast
cancer patients with family history of breast or ovarian
cancers was 24.8% in the KOHBRA study interim report
[32]. Notably, BRCA2 mutation was more common than
BRCA1 mutation in our study, compared with previous
small clinic-based studies [25–27]. This finding is consis-
tent with other studies showing BRCA2 mutations appear
as or more commonly than BRCA1 mutations in clinic-
based Asians, a difference from other ethnic groups [34].
According to high-risk groups in this study, mutation of
BRCA1/2 genes were identified in 8.5% among early onset
patients, in 17.7% among bilateral breast cancer, in 50.0%
Table 5 BRCA1/2 and BRCA2 mutations according to family struc-
ture in patients with early onset breast cancer diagnosed at B40 years
Age Family structure p value
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among patients with both breast and ovarian cancer, in
5.9% among male breast cancer patients, in 7.6% among
patients with cancer of multiple organs, and in 27.1%
among patients having two or more of these high-risk
factors. There are few previous smaller studies of Korean
patients which report BRCA mutations by individual risk
category and several of these include patients with family
history [24, 27]. BRCA1/2 mutations in Korean patients
with early onset regardless of family history were detected
in 10.4–18.3% in the previous studies (Table 7) [23, 26,
32]. The wide variation in reported prevalence of BRCA1/2
mutation in patients with early onset could be related to
variation in number with family history of breast cancer in
these studies. When the group of early onset patients under
35 years was considered, we found prevalence of 10% for
BRCA1/2 mutations with no other risk factor. The mutation
rate increased up to 25.9% for the early onset patients with
other risk factor. Therefore, additional risk factors increase
the likelihood of BRCA1/2 mutation among young
patients.
Two studies reviewed the prevalence of BRCA1/2
mutations in breast cancer patients in terms of ethnic dif-
ference, finding that those diagnosed at a younger age
(mostly under 35 to 45-year old) had prevalence of 5–10%
among various races [24, 34]. On the other hand, the
prevalence of BRCA1 mutation was particularly high in
African-American patients diagnosed before age 35 years
(16.7%), compared with young Hispanics (8.9%), non-
white Hispanics without Ashkenazi Jewish ancestry
(7.2%), and Asian-Americans (2.4%) [35].
Family structure can affect BRCA gene mutation rate
and the accuracy of mutation probability models. BRCA1/2
mutations were detected in 13.7% of the limited family
structure and in 5.2% of the adequate family structure.
Family structure was a significant predictor of mutation
status [18]. However, there was no significant difference of
BRCA gene mutations between family structures in our
study.
The prevalence of BRCA1/2 mutations in bilateral breast
cancer patients in Korea was 17.7% in our study and was
higher than 15.4% prevalence in a previous small study
[27]. BRCA1/2 mutations of bilateral breast cancer in other
ethnic countries showed both 29.6% in high-risk Jewish
families and in Polish patients with having 46.9–82.4%
positive familial history [36, 37].
There is a lack of studies about the prevalence of
BRCA1/2 mutations in male breast cancer in Korea. Two
(25%) BRCA2 mutations and no BRCA1 mutation were
reported among eight male breast cancer patients in a small
study [27]. However, the patients with mutation also had
Table 6 Frequency of BRCA1
and BRCA2 mutations in high-
risk breast cancer patients
without family history of breast
or ovarian cancer
a Frequency in disease-causing
mutation (n = 65)
b Novel
c Detected in only Korean
BIC nomenclature Effect on amino acid na %
BRCA2 7708C[T p.Arg2494X hetero 6 9.2
BRCA1 509C[A p.Tyr130X hereto 4 6.2
BRCA2 5804delTTAA p.I1859KfsX3 hetero 3 4.6
BRCA2 6952delGAb p.Asp2242PhefsX2 hetero 3 4.6
BRCA1 1041delAGCinsT p.Ser308X hetero 2 3.1
BRCA1 3746insA p.Glu1210ArgfsX9 hetero 2 3.1
BRCA1 5615del11insAc p.Val1833SerfsX7 hetero 2 3.1
BRCA1 1630dupG p.Lys505X hetero 2 3.1
BRCA2 1627A[T p.Lys467X hetero 2 3.1
BRCA2 2041dupA p.I605NfsX11 hetero 2 3.1
BRCA2 8542G[Tb p.Glu2772X hetero 2 3.1
BRCA2 9219T[Gb p.Tyr2997X hetero 2 3.1
BRCA2 9481delA p.Thr3085GlnfsX19 hetero 2 3.1
BRCA2 999del5 p.Asn257LysfsX17 hetero 2 3.1
Table 7 Prevalence of BRCA1
and BRCA2 mutations among
early onset breast cancer
patients with or without familial
history of breast or ovarian
cancers in Korea
a Two cases of both BRCA1
and BRCA2 mutations
Ahn et al. [26] Kang et al. [23] KOHBRA
study-interim
report [32]
No. of cases tested (Age) 183 (Age \35) 60 (Age \40) 513 (Age B40)
History of familial breast or ovarian cancers (%) 24 (13.1) 8 (22.0) 181 (32.0)
BRCA1 mutation (%) 13 (7.1) 6 (10.0) 48 (9.4)
BRCA2 mutation (%) 6 (3.3) 5 (8.3) 43 (8.4)
BRCA1/2 mutations (%) 19 (10.4) 11 (18.3) 91a (17.7)
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familial breast cancer history. Our study had a small
number of male breast cancer patients and BRCA2 muta-
tion was detected in only one (5.9%) patients. The BRCA
mutations in male breast cancer without familial breast
cancer history are usually undetected and if detected, it is
almost always in BRCA2 gene.
The prevalence of BRCA2 mutation in male breast
cancer varies from 4 to 40% according to racial differ-
ences. This variance might be related to the different rates
of familial breast cancer history [38–43]. On the other
hand, a recently published study accounted for 16%
BRCA2 mutation of 115 male breast cancer cases from the
United States, including 40% for breast cancer families and
13% for non-familial breast cancer. The study suggested
that family history is not a strong predictor of carrying a
mutation in males and males who develop breast cancer
should be screened for mutations in BRCA2 [44].
The prevalence of BRCA1/2 in multiple organ cancer
cases in our study (7.6%) was lower than previously
reported (9.1%) for cases without familial history in a
previous small study, which also showed 50% with
BRCA1/2 mutations in cases with familial breast cancer
history [27]. In our study, the other primary cancer sites in
breast cancer patients were 46 thyroid cancers, 6 uterine
cancers, 5 kidney cancers, 2 stomach cancers, 2 rectal
cancers, 2 tongue cancers, 1 liver cancer, 1 pancreatic
cancer, and 1 bone cancer. Five BRCA1/2 mutations were
detected in 2 thyroid cancers, 2 kidney cancers, and 1 bone
cancer, respectively (Table 8). It would seem that genetic
testing should be considered whether or not a specific
primary cancer is genetically related to breast cancer. For
example, the International Consensus Conference on
Breast Cancer Risk, Genetics, and Risk Management sug-
gested as candidates for genetic counseling and testing for
breast cancer, any patient who has had a family history of
prostate cancer, thyroid cancer, sarcoma, endometrial
cancer, adrenocortical cancer, brain cancer, or pancreatic
cancer—although these involve less strict criteria [1].
A study reported that the germline mutation rate in
BRCA1 was 2.7% in 37 Korean sporadic ovarian cancer
patients unselected for family history, which was slightly
lower than rates obtained in other countries [45]. The
prevalence of BRCA1/2 mutations in patients with both
breast and ovarian cancer in our study was 50% and higher
than that in Myriad data (20%), although the number of
cases were small [46]. This high prevalence supports cur-
rent practice guidelines of genetic testing for all patients
with breast and ovarian cancers, regardless of age or family
cancer history [11].
Although germline mutations were scattered through the
BRCA1 and BRCA2 genes, the BRCA1, 509C[A gene
which was identified separately in four unrelated patients,
and the BRCA2, 7708C[T gene which was identified
separately in six unrelated patients, are the most frequent
mutation in either genes and accounted for 16 and 15% of
mutations detected in BRCA1 and BRCA2 respectively in
this study of Korean women. 509C[A gene was also
detected in Asian population and 5615del11insA were
detected in only Korean patients in the BIC database. The
BRCA2, 7708C[T gene was detected in Asian and West
European population and detected frequently in Korean
patients in the previous studies [23–25, 27–29]. These
genes would be possible candidates for founder mutations
of BRCA1/2 in high-risk Korean breast cancer patients.
However, defining founder genes in Korean breast cancer
patients should be approached carefully, because there is
no data of mutation frequency in the Korean general pop-
ulation and additional data about BRCA mutations is
required even though the KOHBRA study was a nation-
wide multicenter study.
The selection of genetic testing criteria would be clini-
cally important because the mutation result might affect the
decision-making for operation method and follow-up
method. Although widely accepted clinical criteria for
referral are usually suggested, genetic testing criteria may
differ between countries based on mutation prevalence
because the prevalence of BRCA1/2 mutations varies con-
siderably among ethnic groups and geographical areas [12].
As the NCCN guideline currently recommends genetic
counseling and genetic testing for any patient with high
risk 10% or more of mutation, the prevalence of BRCA1/2
mutations in high-risk breast cancer patients without family
history of breast or ovarian cancer—noted in this study—
may play a key role for genetic testing criteria in Korean
breast cancer patients with high risk of mutation. BRCA-
PRO and Myriad II, two of the most commonly used
















66 2 3 7.6
Thyroid cancer 46 1 1 4.3
Uterine cancer 6 0 0 0.0
Kidney cancer 5 1a 1a 40.0
Stomach cancer 2 0 0 0.0
Rectal cancer 2 0 0 0.0
Tongue cancer 2 0 0 0.0
Liver cancer 1 0 0 0.0
Pancreas cancer 1 0 0 0.0
Bone cancer 1 0 1 100.0
a One patient with kidney cancer had both BRCA1 and BRCA2
mutations
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computer predictive models on clinical expertise, show
accuracy of approximately 80% for whites with strong
personal and/or familial history of breast, ovarian, and/or
male breast cancer. However since these models show
underestimation of Asian mutation carriers because of their
differences in performance by race/ethnicity, using these
models to predict the BRCA1/2 mutation probability among
Korean patients may result in inaccuracies [34]. Therefore,
large nationwide trials like the KOHBRA study are needed
to continue developing the appropriate guidelines for
genetic counseling, genetic testing, and management as
well as the suitable predictive model for BRCA1/2 mutation
patients or carriers in Korea. It is important to evaluate
whether the difference of BRCA1/2 mutation prevalence
exists between Koreans and other races. Identifying racial
differences in genetic or lifestyle factors, which may
modify the cancer risk of BRCA1/2 mutations, is also
a priority for future research. So far, the management for
BRCA1/2 mutation patients or carriers in Korea is recom-
mending that application is individually based on the
prevalence data of BRCA1/2 mutation of the KOHBRA
study, as well as the worldwide guidelines such as the
NCCN guideline or the International Consensus Confer-
ence guideline.
Our study has some limitations despite being a large
multicenter nationwide study. Three different screening
methods for testing BRCA1/2 mutations were performed
although most patients were tested with the F-CSGE
method. This heterogeneous screening method might affect
the prevalence of BRCA mutation. Also, the number of
patients varied according to risk groups. For instance, the
prevalence of BRCA1/2 mutations in male breast cancer
patients as well as in patients with breast and ovarian
cancer in this study must be interpreted with caution due to
the very small number of subjects. Another limitation
involves the various additional primary organ sites for
patients with multiple organ cancers. Additional primary
cancer sites in breast cancer patients in our study were
thyroid, uterus, kidney, stomach, tongue, rectum, liver,
bone, and pancreas. Whether cancers from these organs are
genetically related to breast cancer or BRCA1/2 mutation
requires confirmation. Besides the differences in number of
cases with familial breast cancer history, the different sites
of multiple-organ cancers might affect the many discrep-
ancies in the prevalence of BRCA1/2 in multiple organ
cancers cases between our study and the previous smaller
study [27].
In conclusion, BRCA1 and BRCA2 mutations were
detected at higher frequency than reported for Korean
sporadic breast cancer patients in those patients with no
family history of breast or ovarian cancer but with other
risk factors of genetic disease. In particular, the patients
with early onset of less than 35 years of age, bilateral
breast cancer, and personal history of breast and ovarian
cancer had greater than 10% prevalence of BRCA1/2
mutations. Genetic testing may be indicated for these high-
risk patient groups.
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